.
MergerLinks Header Logo

New Deal


Announced

Completed

Nordic BioSite completed the acquisition of LubioScience.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Switzerland

Cross Border

Majority

Biotechnology

Acquisition

Private

Friendly

Single Bidder

protein biochemistry

Completed

Synopsis

Edit

Nordic BioSite, a supplier of products for research and diagnostics, completed the acquisition of LubioScience, a company that offers a select range of R&D products for protein biochemistry, cell culture and general lab reagents of high quality. Financial terms were not disclosed. “Switzerland is a key research hub in Europe and hence we have been eager to be present there to help existing and new suppliers gain access to this fast-growing market. LubioScience has been #1 on our target list for a long time as we have been impressed with the success they have had in the Swiss market. I am sure there are many things we can learn from their success to replicate within the Group, just like we can transfer our commercial and operational best practices to LubioScience” Sune Schmolker, Nordic BioSite CEO.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US